III. Conclusion

In today’s environment of increased scrutiny of corporate conduct and increasingly large expenditures for prescription drugs, it is imperative for pharmaceutical manufacturers to establish and maintain effective compliance programs. These programs should foster a culture of compliance that begins at the executive level and permeates throughout the organization. This compliance guidance is designed to provide assistance to all pharmaceutical manufacturers as they either implement compliance programs or re-assess existing programs. The essential elements outlined in this compliance guidance can be adapted to the unique environment of each manufacturer. It is the hope and expectation of the OIG that the resulting compliance programs will benefit not only federal health care programs and their beneficiaries, but also pharmaceutical manufacturers themselves.

Dated: April 23, 2003.

Janet Rehnquist,
Inspector General.

OUR PROMISE Being a healthcare whistleblower can feel like David taking on Goliath. We help level the playing field.

Our law practice is dedicated exclusively to representing healthcare whistleblowers who are willing to take a stand against unscrupulous corporations that are ripping off our government. Whether the fraud involves __________, we pride ourselves on unparalleled level of service, support and legal assistance for our clients.
Contact Us